about
Perturbation of microRNAs in rat heart during chronic doxorubicin treatmentUtility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicityCancer treatment-related cardiac toxicity: prevention, assessment and management.Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective studyAnthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up.CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patientsAnthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.Echinochrome A protects mitochondrial function in cardiomyocytes against cardiotoxic drugs.S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodelingPotential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.The utility of cardiac stress testing for detection of cardiovascular disease in breast cancer survivors: a systematic review.Clinical characteristics of patients with cancer referred for outpatient physical therapy.Quantifying Drug-Induced Nanomechanics and Mechanical Effects to Single Cardiomyocytes for Optimal Drug Administration To Minimize Cardiotoxicity.Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.Anthocyanin Attenuates Doxorubicin-Induced Cardiomyotoxicity via Estrogen Receptor-α/β and Stabilizes HSF1 to Inhibit the IGF-IIR Apoptotic Pathway.Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell deathExpert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.Cardiotoxicity.Chemotherapy-induced cardiomyopathy.Anthracyclines as effective anticancer drugs.Cardiotoxicity of antineoplastic agents: what is the present and future role for imaging?Developing a rat model of dilated cardiomyopathy with improved survivalInteraction of anthracyclines with iron responsive element mRNAs.Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity.Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.ALDH2 attenuates Dox-induced cardiotoxicity by inhibiting cardiac apoptosis and oxidative stress.Cardio-Oncology: mechanisms of cardiovascular toxicity.An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.Use of Human Pluripotent Stem Cell Derived-Cardiomyocytes to Study Drug-Induced Cardiotoxicity.Micro-Economics of Apoptosis in Cancer: ncRNAs Modulation of BCL-2 Family Members.
P2860
Q27335046-DF773B74-AC48-465C-AE36-73BE25D6D942Q28301317-E331217A-0AB3-4363-976E-FF128DFF3FFEQ30276456-E35C592B-A90C-4C84-9A01-2D430700BF64Q30276527-6EB62BD6-2238-4A57-857D-1963F421E841Q33341069-B0362101-6D22-4D16-86A3-B66E7D506FEFQ33578496-0E4D2042-547A-46F1-9ABD-F399BB5E47C8Q33591741-AEE5741E-2B15-40CC-8BD1-DC8A289E5E93Q33729389-AD5DBF19-A327-4A56-B7E3-2F9A8190E1EDQ33736748-71811A45-1F4B-4A82-A40B-6AA975411EC1Q34062431-07CF0A76-7C9B-4B82-B28B-DED03018615CQ34333236-6B627AAE-D2DE-4E1A-8A74-953CE23C827DQ35043809-9DE1874F-B93A-49B2-900D-12279D2B59A0Q35255014-C6CC3379-4A75-41F8-BC00-F52C54D69FD2Q35887269-1F3ED19C-0A06-48C1-B5EF-A11FD12CDC66Q36568908-B2A2FE69-8B49-4E29-9B11-80000C64683BQ37118928-BD4B7F46-7ED2-43EE-A98D-9E35F0C9301DQ37286660-DF9B33D4-A81D-435E-A8FA-23B5CFB34823Q37330749-39623CC6-1EDE-43A9-BAC0-8DBC480C2A4EQ37372203-81CDDD25-A299-4FCE-9A11-A44B1BF430C9Q37799924-8BB9EDF8-92C7-48CB-8EFC-2E070CB98F92Q37867085-60175345-B061-43DD-92DB-8318F58BEC78Q38090650-55C64EA8-1B47-44F1-8EB7-2F0B017A007FQ38225977-E465F2D5-FCDF-4B3F-AB7F-03175B80B05AQ39524713-54CA96F0-3682-4037-9A6B-FA5BCFB3B0FFQ41597593-39C67ABF-7EFE-4F60-B9FE-6E390C1ECA7AQ41717594-8C88E7B4-A399-43BC-9E1F-110062365009Q41896006-B50B0CD4-31B1-4D08-BB54-8EE437B18116Q42061022-68E7069E-1E0E-4DCB-AA49-4890CE5AFB2EQ48109228-23D2B364-DC06-4559-96A5-D862146D64B2Q48357803-FF9695E7-6ED4-4DEE-87E6-7B18719D2691Q52428477-1A955053-F61C-4598-88F3-3BEA8DDC15BFQ55065193-31F159E7-32D6-4087-8203-C0C0607FCA48
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Anthracycline cardiotoxicity.
@ast
Anthracycline cardiotoxicity.
@en
type
label
Anthracycline cardiotoxicity.
@ast
Anthracycline cardiotoxicity.
@en
prefLabel
Anthracycline cardiotoxicity.
@ast
Anthracycline cardiotoxicity.
@en
P2860
P356
P1476
Anthracycline cardiotoxicity.
@en
P2093
Michael S Ewer
Robin L Jones
P2860
P304
P356
10.1517/14740338.5.6.791
P407
P577
2006-11-01T00:00:00Z